Not only altered PSA-NCAM levels have been reported in depression, schizophrenia and neurodegenerative disorders [60], [67]–[70], but also diminished NCAM levels were evidenced in some of these pathologies and in animal models of these diseases [45]–[49], [71], [72]. Here, NCAM1 is linked to depressive symptom measurement.